EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Avidity Biosciences's enterprise value is $1,670.16 Mil.
Avidity Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $10.90 Mil. Therefore, Avidity Biosciences's EV-to-Revenue for today is 153.27.
The historical rank and industry rank for Avidity Biosciences's EV-to-Revenue or its related term are showing as below:
RNA'
s EV-to-Revenue Range Over the Past 10 Years
Min: -29.64 Med: 65.97 Max: 458.96
Current: 153.27
During the past 7 years, the highest EV-to-Revenue of Avidity Biosciences was 458.96. The lowest was -29.64. And the median was 65.97.
RNA's EV-to-Revenue is ranked worse than 90.99% of 988
companies
in the Biotechnology industry
Industry Median: 7
vs RNA: 153.27
The historical data trend for Avidity Biosciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Avidity Biosciences's EV-to-Revenue
For the Biotechnology subindustry, Avidity Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avidity Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avidity Biosciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Avidity Biosciences's EV-to-Revenue falls into.
Avidity Biosciences's current Enterprise Value is $1,670.16 Mil.
Avidity Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avidity Biosciences's share price for today is $26.17.
Avidity Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avidity Biosciences EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Avidity Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RNA has been successfully added to your 